Compare Bristol-Myers Squibb Co (BMY) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs MINISO Group Holding Ltd — how do they compare? Bristol-Myers Squibb Co trades at $59.01 (market cap $116.30B), while MINISO Group Holding Ltd trades at $12.68 (market cap $3.46B). The key difference: Bristol-Myers Squibb Co is far larger — about 33.6× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays the higher dividend (5.78%). Which is the better fit depends on your goals.
| BMY | MNSO | |
|---|---|---|
Market Cap | $116.30B | $3.46B |
Sector | Health | Technology |
52-Week High | $62.37 | $26.63 |
52-Week Low | $42.60 | $11.30 |
Enterprise Value | $152.24B | $4.13B |
Dividend Yield | 4.42% | 5.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
MNSO trades at $11.42, down 3.14% on the day, reflecting recent volatility. The stock shows mixed signals with a bearish technical trend but solid fundamentals, including a P/E of 11.73 and net income margin of 8.98%. Recent corporate actions include a $0.38 dividend and a HK$2 billion share repurchase program announced on June 29, 2026, signaling management confidence. Q1 2026 earnings beat expectations with EPS of $0.591 versus $0.238 expected, though prior quarters missed estimates.
Outlook is cautiously optimistic given strong profitability metrics and shareholder-friendly actions, but risks include margin pressures from overseas expansion and technical bearishness. With 75% analyst buy ratings and an undervalued GF Score per GuruFocus on June 29, 2026, the stock offers value if execution improves, though investors should monitor earnings consistency and global economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
